Paris-based Lucis has raised a $20 million Series A to expand its ‘AI-powered’ preventive health platform across Europe, four months after closing an $8 million seed round.
Lucis competes most directly with Thriva in the arena of UK-style at-home biomarker testing, Neko Health in European preventive-health positioning, and Function Health as the US benchmark for AI-enabled longevity medicine.
The fresh capital will be used to expand into Spain, Germany and Italy by the end of 2026, while investing further in personalisation, longitudinal monitoring and clinical safety. Lucis has also signed partnerships with laboratory groups including Eurofins and Randox.
The funding round was led by Singular, with participation from General Catalyst, Y Combinator and angel investors including backers of Runna, Céline Lazorthes of Resilience, and Manu Lecomte. The new funding brings Lucis’s total raised to $28 million.
Founded in 2025 by Maxime Berthelot and Baptiste Debever, Lucis gives users a data-led picture of their health by analysing more than 110 blood biomarkers, covering metabolic health, hormones, cardiovascular risk, inflammation and nutrient levels.
Those results are fed into an AI health companion app, which combines biomarker data, medical context and follow-up testing to recommend changes across nutrition, supplements and lifestyle. Lucis says its recommendations are reviewed by physicians and refined as new data comes in.
The company claims more than 10,000 users across France, the UK, Ireland and Portugal, and says it has processed more than one million biomarker tests. Among users who completed a six-month follow-up, 75% improved at least three biomarkers without medication, while more than 80% chose to retest.
Lucis is pitching itself against state-run European healthcare systems which are built around sickness rather than prevention. The company says 99.9% of its users had at least one biomarker outside optimal ranges at initial testing, often without knowing it.
“We are making prevention the default, rather than a privilege,” said Maxime Berthelot, Lucis co-founder and CEO in a statement.
Singular co-founder and GP Jeremy Uzan said Lucis had reached “remarkable velocity”, citing its 10,000 users, measurable outcomes and “compounding data advantage” in Europe’s emerging preventive health category.
